SpectraCure has developed a new method for treatment of recurrent prostate cancer. The aim of the treatment is to eliminate cancer cells using laser light in combination with a light-activated drug. To date, there is no established standard of care for patients with localized recurrent prostate cancer.
SpectraCure has been developing the method for many years and is currently running a clinical trial. The trial is conducted at leading cancer research clinics: Princess Margaret Cancer Centre in Toronto, University College London Hospital, Memorial Sloan Kettering Cancer Center in New York, and Skåne University Hospital in Malmö.
We aim to run the study at clinics at the forefront of prostate cancer treatment.
The aim of the study is to evaluate interstitial photodynamic therapy (PDT) for treatment of recurrent prostate cancer. Interstitial PDT is a further development of traditional PDT, a successful treatment for skin cancer.
The SpectraCure treatment involves intravenous injection of a light-activated drug and light delivery to the tumor. The procedure is performed using SpectraCure’s Q-PRO® system, which delivers light via optical fibers inserted into the prostate. The drug used in the trial is called verteporfin, which has been used for many years in clinical practice and is approved for treatment of eye diseases.
SpectraCure’s Q-PRO® system includes a laser device and a software called IDOSE ®, which calculates the dose of light to be delivered to the prostate. The light dose is adjusted continuously during the treatment to achieve an adequate dose to the entire tumor. The light dose is adjusted to eliminate the cancer cells and at the same time spare healthy surrounding tissue.
Treating cancer tumors with a light-activated drug and light is an established method, but treatment of tumors inside the prostate with individualized dosimetry is novel.
Treatments offered to patients with recurrent prostate cancer vary. Some patients are offered surgical removal of the entire prostate, while others are offered hormone therapy. All treatment options carry a significant risk of side effects, which is why there is a need for focal therapies with limited side effects. Today, specialized clinics offer focal therapies such as High-Intensity Focused Ultrasound (HIFU) or Cryo for treatment of localized prostate cancer. However, these treatments do have limitations and are not widely available.
The most common treatment option is hormone therapy, which is used to lower the level of androgens (male sex hormones) in the body. Because of the severe side effects associated with hormone therapy, many physicians postpone the introduction of hormones as long as possible. In the meantime, active surveillance is applied to monitor disease progression.
SpectraCure’s clinical trial follows the international standard for drug trials; Good Clinical Practice (GCP), and ethical guidelines set by the WHO, which ensures that data and results are accurate and that the rights and privacy of participants are protected.
The clinical trial is approved by regulatory authorities and ethical committees in Canada, the UK, the US and Sweden.
Each study site is responsible for the recruitment and selection of participants. Contact your responsible physician if you are interested in participating in our clinical trial.